More than 180 rural hospitals in the United States have closed since 2005, according to the Chartis Center for Rural Health, while providers spend over $25 billion annually on claims adjudication, with nearly $18 billion of that tied to claims that are ultimately paid, according to Premier Inc.

That’s not a demand problem. It’s an administrative one. And increasingly, it’s a technology infrastructure problem tied to how work is managed, measured, and automated.

And for rural hospitals operating with limited staff and thin margins, that level of inefficiency isn’t just costly; it’s unsustainable.

The Work Behind Getting Paid

In most healthcare organizations, a claim isn’t processed once and paid; it’s worked over and over again.

It gets handed off, corrected, resubmitted, and appealed. Each of those touch points requires human time, and each one introduces delay and cost. According to the Council for Affordable Quality Healthcare (CAQH), administrative transactions in healthcare still cost the system tens of billions annually, with a sizable portion being driven by manual processes.

Even more concerning, a large share of denied claims that ultimately get paid requires intervention, meaning that much of the work happening inside financial operations is rework, not value creation, as highlighted in the Premier analysis.

That’s where a lot of margins disappear.

Why Rural Hospitals Feel It First and Hardest

Large health systems can absorb inefficiency. Rural hospitals can’t.

Nearly half of rural hospitals are operating at a financial loss, and many are at risk of closure due to sustained margin pressure, according to the Chartis Center report.

When you have smaller teams, fewer specialists, and less redundancy, every extra touch matters. Administrative staff aren’t just processing claims; they’re juggling eligibility issues, documentation gaps, payer requirements, and follow-up.

There’s no buffer.

In larger systems, inefficiency is expensive. In rural hospitals, it’s existential.

Complexity Is Growing Faster Than Capacity

Payers are continuing to increase requirements, which means more edits, more prior authorizations, and more documentation specificity. A 2024 American Medical Association survey found that physicians complete an average of 43 prior authorizations per week with many reporting delays that directly impact care delivery.

At the same time, systems remain fragmented, and workflows are rarely aligned across the financial lifecycle. The result is simply more work per claim. Not more reimbursement. Not better outcomes. Just more effort required to get paid.

Where AI Fits and Where It Doesn’t

There’s a lot of discussion right now about AI solving administrative burden in healthcare. But in practice, AI is not a replacement for the people doing this work, especially in rural hospitals.

The reality is that a substantial percentage of the issues that require human intervention are tied to nuance. Documentation context, payer-specific rules, and incomplete information aren’t problems you can fully automate.

Beyond automating repetitive tasks, AI is increasingly being used to improve visibility—helping organizations analyze claims data, identify patterns, and enhance payment accuracy across workflows, as outlined by McKinsey & Company

But resolution still requires human judgment.

In rural hospitals, the goal isn’t to replace people. That’s not realistic, and it’s not the right objective. The goal is to reduce the amount of unnecessary work those people are being asked to do so they can focus on more high-value work.

AI works best as a force multiplier, helping teams focus on what actually requires expertise instead of chasing preventable problems.

The Real Opportunity: Reducing the Work, Not Just Automating It

Too often, the focus is on how to process work faster. The better question is, why does the work exist in the first place?

If a claim is touched multiple times before it’s paid, speeding up those touches doesn’t solve the problem. It just accelerates inefficiency.

The opportunity is to reduce the number of touches altogether.

That starts with understanding where work is being created, where breakdowns are happening, where rework is being introduced, and where effort is being duplicated. From there, organizations can begin to redesign workflows to prevent issues instead of reacting to them.

That’s where both operational discipline and technology need to come together.

What’s at Stake

Rural hospitals aren’t just healthcare providers; they’re access points for entire communities.

When they close, patients don’t just lose convenience, they lose access. The Chartis Center for Rural Health continues to warn that rural hospital closures create care deserts, forcing patients to travel significantly farther for essential services.

We’re investing heavily in clinical innovation and AI across healthcare. But if the administrative side of the system continues to erode financial stability, those investments won’t matter for the organizations that can’t afford to stay open.

Administrative complexity is not a secondary issue. It’s a structural one. Until we address it by reducing unnecessary work, improving visibility, and supporting the people doing the work, rural hospitals will continue to operate at a disadvantage they can’t overcome.

About Matt Seefeld
Matt Seefeld, CEO of MedEvolve, is a healthcare executive with more than 25 years of experience in the assessment, design, and implementation of process improvement programs and technology development for the healthcare revenue cycle. He focuses on reducing administrative complexity and improving operational performance across healthcare organizations.

What You Should Know

• A new survey by the Deloitte Center for Health Solutions reveals that 62% of diagnostics manufacturer executives believe future growth depends entirely on adopting a business-to-business-to-consumer (B2B2C) operational model.
• The research highlights an immediate strategic disconnect: while providers rank test ordering as their single greatest clinical friction point, manufacturers mistakenly over-index on results interpretation as the primary challenge.
• Rising consumerization is reshaping the market landscape, with 76% of provider respondents stating that consumer- and patient-initiated testing demands will fundamentally alter diagnostics over the next three years.
• Interoperability remains an acute infrastructure hurdle; 74% of healthcare providers admit that their current database systems are completely disconnected and un-integrated across the end-to-end diagnostic journey.
• To survive the expansion of home diagnostics and wearables, manufacturers must embed AI natively within EHR workflows, automate prior authorizations, and deliver highly personalized, visual data context directly to consumers.

The B2B2C Migration: Why Diagnostics Manufacturers Must Shift from Product Vendors to Workflow Partners

The global diagnostics manufacturing sector is currently navigating an aggressive, multi-directional market disruption. On the consumer front, patients are rapidly adopting sophisticated, distributed health tools—utilizing virtual healthcare portals, direct-to-consumer (DTC) self-ordered testing, digital health applications, and advanced wearable sensors to independently track, interpret, and manage their baseline biological data. Concurrently, traditional healthcare providers—encompassing independent commercial laboratories, hospital systems, and imaging facilities—are under intense operational pressure to deliver faster, highly streamlined, and deeply personalized clinical experiences or risk permanently losing market share to agile, consumer-focused tech entrants.

While these shifts point directly toward a data-driven, consumer-centric, and personalized ecosystem, legacy clinical models will not vanish overnight. Traditional healthcare providers still generate the dominant share of core revenue for diagnostics manufacturers. The pressing strategic question for corporate boards is no longer how to bypass the traditional system, but how manufacturers can actively equip their core provider customers to survive and compete in a consumer-driven marketplace.

To assess industry readiness for this transition, the Deloitte Center for Health Solutions conducted parallel surveys of 50 diagnostics manufacturer executives and 50 healthcare provider executives, supplemented by 20 in-depth interviews with industry leaders. The findings reveal a stark reality: 62% of manufacturers recognize that future growth hinges on a next-generation B2B2C blueprint. However, deep structural disconnects in stakeholder engagement, workflow integration, and consumer personalization threaten to stall this critical evolution.

Dissecting the Three Core Provider Disconnects

Before manufacturers can capture the emerging B2B2C opportunity, they must re-engineer how they interact with their primary healthcare provider customers. Deloitte’s research exposes three critical disconnects where manufacturer strategies are misaligned with localized provider realities:

1. The Problem-Solving Disconnect: In the study, providers explicitly identified test ordering as the single heaviest friction point in their daily clinical pipeline. Manufacturers, conversely, focused their innovation efforts on result interpretation. To bridge this gap, forward-looking manufacturers must look past physical diagnostic kits to expand their offerings into automated software and workflow services.
2. The Stakeholder Disconnect: Surveyed manufacturers stated that their primary account contacts remain hospital procurement offices and channel partners—the traditional buyers who execute contracts. Providers, however, counter that the individuals who actually command clinical adoption and long-term utilization are ordering clinicians, lab directors, and service-line leaders. Manufacturers are over-investing in procurement relationships while under-investing in the clinical stakeholders who dictate actual product adoption.
3. The Engagement Disconnect: Providers heavily prioritized peer-to-peer clinical education, medical conferences, and intuitive, digital self-service web portals to research technology independently. Manufacturers, by contrast, continue to deploy high-frequency field sales teams, an outreach method that several provider interviewees described as overly frequent and lacking clinical value.

Harnessing Platform-Based AI and Interoperable Moats

The urgency to fix these engagement gaps is accelerating. 76% of provider respondents state that consumer-initiated testing demands will radically transform the diagnostics footprint over the next three years. Furthermore, 92% of providers are already actively offering or exploring patient-initiated testing pathways, compared to just 70% of manufacturers—proving that frontline clinics are absorbing the brunt of changing consumer behaviors.

As testing decentralizes into the home and retail environments, providers are becoming nodes in a distributed care network. Consumers expect visual, contextually clear results that move past raw numbers to outline actionable next steps. To help providers scale this level of personalization, manufacturers must prioritize comprehensive data and workflow integration. Currently, the tech stack is highly fragmented: 74% of providers report that their backend systems are entirely un-integrated across the end-to-end diagnostic journey.

This data isolation creates a significant entry point for platform-integrated Artificial Intelligence. Rather than deploying isolated, standalone algorithms, the competitive advantage belongs to integrated platforms that connect data across revenue cycles, automated prior authorizations, and native EHR workflows. 66% of provider executives state that personalized workflow integration will be exceptionally important over the next three to five years. Manufacturers that embed their testing infrastructure within these automated loops can capture a continuous, longitudinal view of patient health extending far beyond the clinical encounter. Those that resist this integration risk being relegated to interchangeable commodity test vendors with zero visibility into consumer behavior and no influence over future diagnostic decisions.

Every year, there are roughly 33.5 million hospital admissions, 155 million emergency department visits, and hundreds of millions of outpatient encounters across the United States. At the same time, healthcare spending has reached $4.9 trillion annually. When patient data, especially for such a large number of healthcare consumers, is fragmented across multiple applications, vendors, and systems, the effect is exponential. It is multiplied across every encounter, every workflow, and every decision, impacting not only quality of care and the patient experience, but also hospital performance and the bottom line. 

As a result, EHR interoperability is becoming central to how healthcare organizations think about sustainability, efficiency, and care delivery at scale. While industry conversations have traditionally focused on interoperability as only a regulatory requirement or technical milestone, the shift is becoming more apparent. 

This shift is also reflected in how healthcare leaders are approaching their technology environments. In a 2026 CHIME survey, nearly 90% of healthcare CIOs reported that vendor consolidation is a priority within their interoperability strategy. There is broad alignment around the need to simplify environments and reduce fragmentation. At the same time, interoperability is still often being approached as something layered onto existing systems rather than a capability built into their EHR core. 

Shifting Interoperability from Project to Infrastructure

Interoperability isn’t a new need or a new concept; for years, health system IT departments have advanced compatibility through interfaces, integrations, and incremental improvements. This approach wasn’t wrong; in fact, it has enabled meaningful progress for more than a decade, and has expanded the ability for healthcare organizations to exchange data across systems. But, each additional connection requires implementation, ongoing maintenance, governance, and costs. Over time, these connections and improvements have also introduced significant complexity to systems that can and should be simple. 

That complexity has caused many health IT leaders to shift how they think about interoperability to the point that it is no longer viewed solely as a series of projects that somehow connect together. Instead, it is increasingly viewed as a continuous capability that must both be sustained and scaled. Despite this new focus on interoperability, only 16% of CHIME respondents reported that interoperability is capable through the core of their EHR system, highlighting the gap between strategic intent and architectural reality.  

Data Says That the Roadblocks are Resulting in Dollar Signs

This dynamic isn’t about knowledge, skill, institutional support, or desire; instead, data points to cost. Healthcare leaders report that the financial burden of integration and ongoing maintenance remains a primary barrier to achieving interoperability at scale, and more than 47% of CHIME respondents cited cost as their biggest obstacle. Even as organizations invest in new technologies and standards, the underlying model can make it difficult to achieve progress without adding complexity. 

Foundational Challenges are Keeping Interoperability at Bay

Cost may be the primary barrier slowing down interoperability for most health IT leaders, but it is  not the only one. The foundational challenges of interoperability have remained consistent and it shows in the data. Vendor unwillingness and delays impact more than 42% of CHIME respondents working towards interoperability, lack of standardization stands in the way for 26% and IT staffing and internal resource constraints block the path for another 37%. In addition to these challenges, 47% of CHIME respondents ranked data silos and system fragmentation as a top concern when it comes to achieving interoperability.

These are not new issues, nor are they the result of a lack of effort. Instead, they reflect the way healthcare technology has evolved over time, typically in response to immediate needs rather than long-term architectural alignment with the hospital’s needs and goals. 

The impact of these challenges becomes clearer when viewed at scale. Across millions of patient encounters each year, fragmented data can contribute to repeated testing, delays in information access, and increased administrative burden. These all contribute to increased financial pressure over time, a pressure made worse by the mounting cost of uncompensated care.  

Since 2000, hospitals have provided nearly $745 billion in uncompensated care. While many factors contribute to this, inefficiencies tied to disconnected systems remain monumental to the broader equation. 

Interoperability as an Enabler of Outcomes

Looking past these challenges, the direction forward is increasingly clear, Interoperability is about connecting systems to enable positive outcomes. In the CHIME survey, 58% of CIOs cited improved care coordination as the most important potential result of interoperability, while 37% pointed to patient safety improvements and cost reduction.

When interoperability functions as intended, it becomes part of the background, a silent partner that seamlessly supports the end goal for all clinicians and patients; the right data in the right hands at the right time. Clinicians need access to complete and timely information. Organizations can reduce duplication and streamline workflows. Patients experience more coordinated care across settings. In this way, interoperability facilitates essential infrastructure of all clinical decisions and outcomes.

The industry has already made significant progress: standards continue to evolve, technologies are advancing, and strategic alignment is stronger than it has been in the past. The next phase of interoperability builds on this progress by establishing these advancements as the foundational core of the EHR and supporting clinical delivery at the point of care. 

As healthcare continues to evolve, the alignment between strategy and architecture will play an increasingly important role. Interoperability is required to be embedded, supported, and sustained as part of the core system. That is where the full value can be realized across the entire care continuum.

About Sandra Johnson

As Senior Vice President of Client Services, Sandra Johnson is responsible for delivering healthcare IT solutions and managing the customer experience to ensure CliniComp’s technology is continuously evolving to meet the changing needs within the healthcare community. Sandra oversees all aspects of the customer lifecycle including account & project management, application support, clinical services, cybersecurity, and learning & development for our global customer base.

What You Should Know

• Wearable technology leader ŌURA has officially launched Oura Ring 5, re-engineering its mechanical and electrical architecture to create a device that is 40% smaller than its predecessor.
• Moving past passive metrics, the latest software update introduces Health Radar, a clinical expansion featuring background tracking of blood pressure signals, nighttime blood pressure drops, and 30-day rolling respiratory data.
• For individuals managing anti-obesity medications, the application debuts GLP-1 Insights, unifying dosing schedules, subjective side-effect metrics, and weight profiles with continuous sleep and biometric tracking.
• The company is building out a connected care infrastructure by integrating an on-demand, AI-enabled clinical triage layer via Counsel Health, allowing users in 43 U.S. states to text licensed physicians directly inside the app.
• Oura Ring 5 is constructed from non-allergenic titanium with an extra-strong physical vapor deposition scratch coating, retails starting at $399, and begins shipping globally on June 4, 2026.

Beyond Awareness to Action: Oura Ring 5 Unveils Proactive Health Radar and Connected Care Pathways

The global consumer wearable sector has reached a critical structural turning point. For the past decade, the market has been dominated by wrist-worn smartwatches that primarily functioned as descriptive biometric scorecards—tracking raw daily step counts, capturing broad heart rate zones, and archiving basic sleep metrics. However, as consumers grapple with complex chronic conditions, rising healthcare costs, and expanding insurance navigation hurdles, the demand for technology has fundamentally shifted.

Modern users are no longer satisfied with passive digital tracking that simply tells them they slept poorly or exercised frequently. They demand proactive, predictive intelligence capable of converting raw biometric noise into structured, clinical systems of action. Furthermore, as behavioral medicine increasingly merges with medical weight management therapies, the hardware housing these insights must evolve past bulky screens to deliver highly discreet, continuous, and lifestyle-integrated forms.

To dismantle the traditional boundaries separating consumer electronics from proactive health optimization, smart ring pioneer ŌURA has announced the global launch of Oura Ring 5. Built on twelve years of categorical engineering, the device combines a massive architectural miniaturization with a comprehensive ecosystem of clinical health records, real-time activity tracking, and on-demand physician integration.

Miniaturizing the Pulse: The Re-Engineered Architecture

The core engineering triumph of Oura Ring 5 centers on a comprehensive overhaul of its underlying hardware parameters, achieving a 40% reduction in total size compared to Oura Ring 4 to establish itself as the world’s smallest smart ring. To construct this thinned, lightweight, non-allergenic titanium silhouette without sacrificing structural data accuracy, ŌURA re-engineered its mechanical, electrical, optical, and battery geometries from the ground up.

The ring’s upgraded biometric signal layer integrates low-profile sensor domes for optimal skin contact, high-efficiency LEDs, and twelve dedicated signal pathways. This advanced hardware baseline guarantees a clean, continuous optical reading across diverse finger structures and skin tones. Crucially, the finger remains the optimal location for consumer biometric sensing. The local digital arteries deliver a clear pulse signal that is up to 100 times stronger than signals captured at the wrist, enabling Oura Ring 5 to track real-world cardiovascular indicators with a level of precision that legacy smartwatches cannot replicate.

Pricing & Availability

Crafted to withstand uninterrupted daily wear, the device features an extra-strong physical vapor deposition (PVD) coating for advanced scratch resistance, along with a dust- and waterproof rating up to 100 meters. Pre-orders open immediately, starting at $399 for base finishes (Silver and Black) and $499 for premium finishes (including modern Gold and Deep Rose), with global shipping scheduled to commence on June 4, 2026.

Activating the Health Radar: Blood Pressure Signals and Sleep Regularity

Alongside the miniaturized hardware, ŌURA has rolled out a sophisticated suite of preventative clinical software applications. Leading this transformation is Health Radar, a proactive monitoring matrix engineered in collaboration with more than 40 in-house medical doctors and Ph.D. scientists. Health Radar continuously analyzes background biometric signals to surface anomalous physiological patterns long before they escalate into acute medical issues.

The primary clinical focus of the radar is the trackable measurement of Blood Pressure Signals. Cardiovascular strain is notoriously invisible during daily activity, obscured by stress, movement, and caffeine consumption. Oura Ring 5 solves this tracking dilemma by monitoring blood pressure patterns during sleep, a critical resting state when the human cardiovascular system outlines its truest condition. The app monitors nighttime dipping trends—alerting users when their biometrics point to a persistent lack of nocturnal blood pressure reduction, which serves as a vital early indicator of long-term cardiovascular risk. Users can also log manual cuff measurements directly into the interface to align real-world diagnostic numbers with their ongoing physiological data streams.

To further expand its sleep and respiratory diagnostics, the platform integrates a 30-day rolling analysis of Nighttime Breathing disturbances. To transition these insights into direct medical care, ŌURA has partnered with home-health respiratory giant ResMed. Members documenting elevated respiratory interruptions can instantly access trusted diagnostic education, complete validated sleep assessments, and connect directly with independent medical professionals to evaluate potential home care pathways.

Hardwiring Care Delivery and GLP-1 Adherence Tools

Oura Ring 5 is positioning itself to serve as a primary, interoperable data link for connected care. Through its newly deployed Health Records module, the platform merges clinical data with daily wearable signals into a single, privacy-first longitudinal record. In the United States, members can securely sync eligible provider portals to import verified diagnoses, active medications, lab metrics, and allergen profiles. This function delivers a direct preview of ŌURA’s commitment under the Centers for Medicare & Medicaid Services (CMS) Health Technology Ecosystem pledge to seamlessly link interoperable clinical infrastructure with everyday biological signals.

To bridge the gap between algorithmic insight and direct medical intervention, the app has embedded an on-demand, AI-enabled clinical triage layer in partnership with Counsel Health. The integration combines specialized medical language models with a dedicated network of licensed physicians. Members can ask complex health questions and receive clinical guidance from certified providers within minutes natively inside the app, a capability launching across 43 U.S. states.

Concurrently, the platform has launched GLP-1 Insights to address the rapid rise of metabolic medication self-management. Instead of forcing patients to manage their therapy across disconnected apps, Oura integrates dosing records, user side-effect logs, and weight tracking directly with core biometric signals like sleep, readiness, activity, and metabolic stress. Through subsequent Lab Uploads, members can import blood biomarker results straight into the app, positioning hard lab data alongside continuous wearable trends for an exhaustive view of metabolic health.

What You Should Know

• Healthcare data navigation and quality platform Garner Health has finalized a $100M Series E funding round, valuing the company at $2.74B.
• Led by Index Ventures, the round features significant continuation backing from blue-chip institutional investors including Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures.
• Garner’s underlying financial infrastructure generates approximately $200M in gross annual recurring revenue (ARR), doubling year-over-year for five consecutive periods.
• The platform addresses systemic waste by parsing an absolute data moat of 60 billion medical records across 320 million patients, evaluating providers using 550 proprietary clinical metrics.
• By routing nearly 2.5 million members to high-performing providers, the platform eliminates out-of-pocket friction for employees while delivering an average 12% reduction in total healthcare spend for enterprise employers in the first year alone.

Reversing Out-of-Pocket Insurance Inflation: How Garner Health’s AI Agent Drives a 12% Cost Reduction

The commercial health insurance landscape is operating under a punitive structural misalignment. For decades, the foundational economic model of American medicine has rewarded volume over absolute value—paying clinical providers for the sheer quantity of procedures they perform rather than the objective safety and durability of their patient outcomes. To protect margins against this systemic inflation, enterprise employers and commercial health plans have steadily shifted financial liability directly onto the consumer. This ongoing cost-shifting has triggered an out-of-pocket spending crisis. Patients face narrower network restrictions and compounding deductibles, left entirely in the dark regarding which physicians consistently practice evidence-based care.

The economic fallout of this information deficit is severe. The single most critical choice in any medical journey is which doctor the patient engages. When individuals lack clear data, they routinely default to unverified referrals or low-performing clinicians. These providers are statistically more likely to drop modern medical guidelines, execute redundant diagnostic testing, and trigger avoidable complications. For self-insured corporations managing massive employee populations, this data fragmentation results in an unmanaged cost spiral that drains corporate capital and strains employee well-being.

To reshape this broken marketplace and transition network design into an auditable system of action, healthcare transparency leader Garner Health has closed a landmark $100 million Series E financing round. Led by Index Ventures, with major participation from premier existing backers including Kaiser Permanente Ventures, Redpoint, Thrive, Sequoia, Founders Fund, and Kleiner Perkins, the injection pushes Garner’s market valuation to $2.74 billion. The fresh capital will be deployed to expand its provider intelligence platform, accelerate AI-native product deployment, and scale its benefits coverage across millions of new enterprise members.

Parsing 60 Billion Records to Eradicate “Ghost Quality”

Garner Health bypasses superficial doctor-rating models by constructing an elite commercial intelligence layer grounded in deep clinical reality. Rather than depending on subjective user reviews, Garner ‘s architecture analyzes a massive claims database encompassing over 60 billion medical records from 320 million longitudinal patient profiles. This infrastructure screens the performance of every clinician in the country across more than 550 proprietary clinical metrics.

To maintain this dataset at scale, Garner has deployed a powerful dual-front AI strategy. Behind the scenes operates the Garner Research Agent, an advanced AI engine built to automatically ingest the latest peer-reviewed medical literature and instantly translate new guidelines into sophisticated data-parsing algorithms. By continuously matching live clinical records against cutting-edge research, the Research Agent verifies that Garner’s physician metrics remain uniquely rigorous and up to date.

On the consumer side, the recently launched Garner Assistant serves as an intelligent front door for members. Operating inside corporate benefits portals, this conversational agent guides individuals through tedious care tasks: locating high-performing doctors, cross-referencing live appointment availability to book visits, and translating complex health plan documentation to check active claims, payments, and reimbursement statuses.

Redefining the Economics of Consumer Behavior Change

The true structural moat of the Garner ecosystem lies in its ability to combine clinical quality measurement with precise consumer financial incentives. Nick Reber, CEO and Co-Founder of Garner Health, noted that meaningful systemic change cannot occur through minor, incremental tweaks. It requires arming individuals with the definitive metrics and clear economic incentives needed to make optimal choices about their care.

Under Garner’s model, when an employee utilizes the platform to select a top-performing provider, their employer steps in to cover the vast majority or entirety of their out-of-pocket costs. This transparent strategy drives immediate results: members pay on average 80% less out-of-pocket to access top-tier physicians. This clear value proposition eliminates care barriers, driving an unprecedented 46% of eligible members to actively utilize the system.

This behavioral shift delivers a dual victory across the value chain. Top-performing doctors help patients recover faster while systematically avoiding unnecessary surgeries and uncalibrated prescription loops. For enterprise customers—which now include nearly 800 large-scale clients like USA Today, Paylocity, the University of Oklahoma, and global agricultural giant Archer-Daniels-Midland (ADM)—the clinical efficiency translates to a 12% reduction in total corporate healthcare spend in the first year alone.

This immediate financial optimization has unlocked rapid commercial scaling. Garner’s gross annual recurring revenue (ARR) has reached approximately $200M, more than doubling for five consecutive years. Concurrently, provider networks like Mercy, Atlantic Health, Teladoc, and Marathon Health are directly embedding Garner’s data engines into their platforms to guide high-quality specialist referrals and audit internal practice patterns.

What You Should Know

• Clinical AI leader Ambience Healthcare has announced a major expansion of its chart-aware intelligence across its enterprise inpatient platform, embedding deep chart reasoning into every phase of a hospital stay.
• Inpatient documentation relies heavily on non-conversational metrics; Ambience’s internal data shows that 70% of clinically important inpatient diagnoses have no signal in a traditional audio transcript.
• The platform addresses severe provider cognitive load by automatically parsing longitudinal histories, daily labs, imaging updates, medications, and vitals to construct source-backed Progress Notes, H&P Notes, and Handoff Summaries.
• In multi-center evaluations across four health systems, Ambience’s chart-aware discharge summaries resolved 91% of information gaps that traditional, standard documentation pipelines had missed.
• Deployed at organizations like Saint Luke’s Health System, the solution has driven an active utilization rate exceeding 70% across core inpatient charting workflows while elevating provider Net Promoter Scores (NPS) by 31 points.

Beyond the Transcript: Ambience Healthcare Unveils Inpatient AI That Reasons Outside the Bedside Recording

The modern inpatient hospital ward operates under an immense, structural data squeeze. Unlike outpatient clinics—where patient interactions are typically episodic, isolated, and highly conversational—inpatient medicine is inherently continuous, fluid, and profoundly complex. Hospitalists routinely manage 15 to 20 highly acute patients simultaneously. Each individual’s clinical trajectory is dictated by a massive, fluctuating stream of day-over-day changes: shifting laboratory values, real-time vital tracking, new diagnostic imaging results, complex medication updates, and continuous clinical orders.

The cognitive load required to manually process and synthesize this unceasing data burden is staggering. Faced with severe time constraints and fragmented shift handoffs, clinical teams frequently default to the dangerous practice of “carrying yesterday’s note forward.” This manual duplication saves immediate time but strips away critical medical context as a patient moves between departments and care teams. When documentation is incomplete or decoupled from the real-world trajectory of the patient, critical care gaps emerge. Most critically for the hospital enterprise, this data fragmentation means diagnoses are under-captured, preventing health systems from translating complex care into accurate billable codes and severely limiting revenue integrity.

To eliminate this documentation crisis and transition hospital medicine into an automated system of action, clinical AI pioneer Ambience Healthcare has announced a major expansion of its chart-aware intelligence across its inpatient platform. By moving past standard ambient technologies that rely strictly on audio recordings, Ambience embeds deep chart reasoning into the entire inpatient arc—ensuring that documentation accurately reflects patient complexity and health systems capture the exact revenue they have earned.

Eradicating the Outpatient Bias in Acute Care Environments

The fundamental limitation of first-generation ambient medical AI is that it was engineered almost exclusively for outpatient care models. In a typical clinic setting, the software operates under a simple framework: a provider enters an exam room, records a conversation with a patient, and an algorithm translates that transcript into a standard clinical summary. In acute inpatient medicine, this model breaks down completely. In roughly half of all inpatient encounters, there is no active conversation to record. Even when a bedside dialogue does occur, the critical clinical variables that actually drive documentation and treatment—such as an overnight drop in hemoglobin or a targeted change in an IV medication dose—are executed entirely outside the speech transcript. Ambience’s analysis confirms the severe shortfall of audio-only approaches, revealing that 70% of clinically important inpatient diagnoses have no signal in the spoken transcript. For high-stakes conditions that dictate corporate coding and financial reimbursement, that blind spot is even wider.

Ambience solves this structural limitation by engineering its AI to read, reason, and continuously monitor the patient’s complete electronic health record (EHR). Dr. Michael Han, Chief Medical Officer at Ambience Healthcare, noted that hospitalists have historically lacked tools built for their true day-to-day workflows. Because the overwhelming majority of what drives inpatient charting never enters an audible conversation, bringing chart-aware intelligence across the entire hospital stay ensures clinicians possess a holistic view of their patients—whether or not an audio recording is ever captured.

The platform embeds this comprehensive chart awareness across five core technical pillars:

• Patient Summary: Instantly compiles a patient’s longitudinal medical history, allowing hospitalists to rapidly orient themselves before stepping into a room.
• History and Physical (H&P) Notes: Dynamically synthesizes bedside interactions with months of background chart data to build compliant, comprehensive intake documentation.
• Real-Time Triage & Diagnoses: Surfaces missed clinical conditions and provides precise ICD-10 coding recommendations backed by objective, verifiable chart evidence.
• Progress Notes: Replaces the legacy copy-forward trap by automatically building each day’s note from the previous day’s record combined with real-time laboratory, medication, and vital updates.
• Handoff & Discharge Summaries: Maintains a continuous synthesis of the hospital stay to enable clean clinical transitions, generating a complete, auditable discharge summary with a single click.

Validated Performance and Widespread Clinician Trust

The operational metrics surrounding Ambience’s inpatient deployment demonstrate a massive leap in data fidelity and provider satisfaction. In evaluations conducted across 66 distinct encounters at four major health systems, the platform’s chart-aware discharge summaries successfully resolved 91% of information gaps that standard documentation workflows had completely missed.

This high level of accuracy has driven rapid enterprise adoption. At Saint Luke’s Health System, provider utilization across H&P notes, daily progress notes, and discharge summaries has soared past 70%, while the organization’s Net Promoter Score (NPS) surged by 31 points. To maintain this clinical trust, nearly 20% of Ambience’s internal workforce is composed of active or trained medical clinicians who are directly embedded within model training, product development, and validation pipelines. This continuous co-design ensures the software functions as a safe, intuitive asset that clinicians trust and rely on daily.

What You Should Know

• Virtual women’s health pioneer Teal Health has announced a strategic research collaboration with the Washington University School of Medicine in St. Louis to expand cervical cancer screening access.
• Orchestrated through the SCORE Initiative at Siteman Cancer Center, the pilot study targets women who have fallen out of touch with the traditional healthcare system and routine preventative care.
• The community-based distribution model deploys Teal Health’s FDA-authorized at-home HPV (human papillomavirus) self-collection kits across trusted spaces like health fairs, food banks, and wellness initiatives in Illinois and Missouri.
• The study evaluates two distinct participant onboarding workflows: a self-directed digital track where women enroll independently using a QR code, and a guided track featuring on-site navigators for real-time enrollment and education.
• Researchers will closely monitor metrics crucial to enterprise clinical validation, including kit return rates, telehealth completion, follow-up care engagement for abnormal results, and overall patient experience.

Moving Outside the Clinic: Why Teal Health and WashU Medicine Are Distributing At-Home HPV Kits via Food Banks

The preventative oncology sector is confronting an acute equity and access crisis within its clinical trial and screening pipelines. Despite decades of evidence proving that routine cervical cancer screenings significantly lower mortality rates, millions of women across the United States remain dangerously overdue for care. The legacy screening model relies heavily on traditional, in-office pelvic exams—a system that introduces severe structural friction for underserved populations. Obstacles like lack of transportation, child care constraints, clinic hours that conflict with hourly work shifts, and past medical mistrust frequently push vulnerable patients out of touch with routine preventative loops.

When women fall through these healthcare cracks, the clinical fallout is devastating. Cervical cancer is highly preventable when caught early, yet data fragmentation and rigid access models mean that diagnoses in underserved communities are often caught at advanced stages. For healthcare systems, academic medical centers, and Medicaid programs, resolving this gap requires moving past traditional campus-based medicine. Innovation must shift toward patient-centered, decentralized infrastructure that can safely meet individuals outside the clinic walls.

To bridge this data wall and build a community-directed system of action, virtual women’s health company Teal Health has finalized a strategic research collaboration with the Washington University School of Medicine in St. Louis. Led by the SCORE Initiative—a dedicated project to increase the uptake of recommended cancer screenings at Siteman Cancer Center based at Barnes-Jewish Hospital and WashU Medicine—the collaboration launches a new pilot study to evaluate a decentralized, community-based distribution framework for cervical cancer prevention.

Activating the Self-Collection Layer via Trusted Spaces

The operational differentiator of the Teal Health-WashU Medicine integration is its focus on utilizing established community trust to drive clinical engagement. Rather than waiting for high-risk patients to navigate complex hospital scheduling lines, the pilot study directly routes Teal Health’s FDA-authorized at-home HPV self-collection kits into local community spaces across Illinois and Missouri. Kits will be distributed at highly accessible, routine touchpoints, including local wellness initiatives, regional health fairs, and area food banks.

To optimize data collection and understand consumer behavior, the Institutional Review Board (IRB)-approved study is actively testing two distinct operational pathways:

• The Self-Directed Digital Track: Women independently enroll in the screening program and activate their profile on-site by scanning a localized QR code with their mobile device.
• The Guided Navigation Track: Specialized on-site medical navigators assist participants with real-time digital enrollment and deliver immediate clinical education during the community event.

By offering a private, comfortable alternative to traditional clinic exams, the platform removes the primary physical and psychological barriers to proactive screening. Researchers will comprehensively track and evaluate multiple backend workflow milestones to measure success: kit return rates, telehealth consultation completion, overall participant satisfaction, and follow-up care engagement timelines for patients returning abnormal results.

Kara Egan, CEO and co-founder of Teal Health, emphasized that for too long, cervical cancer screening has lacked the operational flexibility to easily fit into the realities of many women’s lives. The collaboration solves this friction by bringing advanced diagnostic capabilities into trusted community environments. This model provides a blueprint for a future where life-saving preventative care is genuinely accessible to everyone, everywhere.

Scaling Interoperable Prevention Across Medicaid Networks

For health plan administrators, academic networks, and community health organizations, the pilot delivers vital, real-world data on how to scale home-based diagnostic operations for historically hard-to-reach demographics. Nicole Miller, BSN, RN, an oncology nurse navigator from Siteman Cancer Network member Phelps Health in Rolla, Missouri, noted that integrating at-home self-collection directly enhances the standard of localized care. It provides a highly secure option for individuals who prefer privacy, serving as an important step toward ensuring cancer prevention is universally accessible.

Michelle Silver, PhD, ScM, an epidemiologist and health services research member at Siteman and associate professor at WashU Medicine, highlighted the broader implications of the study. Silver noted that the collaboration provides an invaluable, real-world lens into the precise mechanics required to engage women who have fallen through the traditional screening infrastructure. The data generated from this pilot could fundamentally reshape regional and national approaches to cervical cancer prevention.

What You Should Know

• Healthcare intelligence leader ConcertAI has unveiled major AI-driven enhancements to its CancerLinQ Suite at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
• Powered by Cara, ConcertAI’s proprietary agentic AI platform, the suite automatically parses structured and unstructured data on a weekly basis across a massive footprint of 13 million patient records.
• The upgraded TriaLinQ module automates patient screening for complex biomarkers and lines of therapy, screening eligible patients 3.3 times faster than manual methods and boosting trial enrollment by up to 50%.
• The PatientLinQ module maps a 360-degree view of patient care, automatically identifying clinical trials where a patient has a 90% or greater likelihood of eligibility based on longitudinal real-world data.
• The system-wide architecture integrates directly into native clinician workflows across more than 900 active sites of care to eliminate point-of-care data fragmentation and close critical care testing gaps.

Bedside Cohorts: How CancerLinQ Leverages 13 Million Patient Records to Direct Precision Oncology

The modern oncology care team operates within a punishing, data-dense clinical paradigm. The velocity of oncology innovation has accelerated exponentially, flooding the sector with novel genomic biomarkers, rapidly expanding lines of targeted therapy, and a complex, highly distributed clinical trial ecosystem. Yet, while the therapeutic options available to fight cancer have multiplied, the frontline software systems used to manage this information have remained stubbornly passive. Doctors are forced to make high-stakes, life-altering treatment decisions during tightly constrained, brief patient encounters, manually sorting through mountains of unstructured clinic notes, pathology reports, and external electronic health record (EHR) files.

When data remains trapped in uncurated formats, the clinical fallout is immediate. Eligible patients are routinely missed for leading-edge clinical trials, critical gaps in biomarker testing go unnoticed, and physicians lack the real-world cohort data necessary to confidently evaluate standard treatment outcomes at the bedside. For enterprise cancer centers, this technical fragmentation slows trial enrollment velocity, increases administrative charting burdens, and compromises patient longevity.

To convert this massive lake of unstructured medical text into a continuous system of clinical action, real-world healthcare intelligence pioneer ConcertAI has unveiled major, clinically intelligent advancements to its CancerLinQ Suite. Formally announced at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the upgrades embed automated trial matching, cohort comparisons, and real-time quality benchmarking directly within the clinician’s native workflow.

Automating the Triage Engine: 3.3x Faster Trial Screening

ConcertAI’s updated architecture addresses the point-of-care bottleneck by shifting clinical data processing from a monthly or quarterly batch review into an automated weekly routine. The engine driving this continuous curation is Cara, ConcertAI’s proprietary agentic AI platform. Engineered explicitly for complex oncology use cases, Cara reads and reasons across a highly secure dataset encompassing more than 13 million patient records across all 50 states, sourcing deep longitudinal data from over 900 distinct sites of care.

This underlying intelligence layer actively powers two core clinical modules inside the provider workflow:

• The TriaLinQ Module: This workflow-integrated module automates the historically manual patient eligibility screening pipeline. By deploying advanced AI models trained to instantly pinpoint specific eligibility determinants—such as distinct biomarker variations, historical lines of therapy, localized cancer progression, and disease recurrence—the platform screens eligible patients 3.3 times faster than traditional manual data abstraction. This rapid triage supports up to a 50% increase in clinical trial enrollment, expanding critical patient access to cutting-edge protocols.
• The PatientLinQ Module: Built to deliver an exhaustive, 360-degree view of the patient journey, this module specializes in surfacing targeted clinical trials where a patient carries a 90% or greater likelihood of structural eligibility. It automatically maps these opportunities against the patient’s exact clinical context, allowing oncologists to instantly compare individual charts against macro real-world cohorts to accurately gauge treatment safety and overall survival outcomes.

Shaalan Beg, M.D., Chief Medical Officer of Oncology at ConcertAI, emphasized that the true validation of oncology technology does not reside in platform complexity, but in whether the software actively protects the clinician at the bedside. By putting real-time cohort comparisons and precise trial matches directly into active care workflows, the CancerLinQ updates deliver an automated asset that actively informs treatment decisions during the critical moments that matter most.

What You Should Know

• Oncology AI innovator Triomics has announced a $22M Series B financing round led by Battery Ventures, pushing its total venture funding past $36 million.
• The expansion round features strategic backing from Lightspeed, Nexus Venture Partners, Y Combinator, Oncology Ventures, and Precision Health Informatics (a subsidiary of Texas Oncology).
• Triomics replaces manual medical chart curation by deploying domain-specific AI agents that ingest unstructured longitudinal records, pathology data, biomarker panels, and radiology reports.
• Peer-reviewed validation published in Nature Digital Medicine documents that Triomics slashes manual chart review times by 67%, while boosting clinical trial matches by 40% and enrollment by more than 30%.
• The platform’s multi-workflow infrastructure has captured rapid adoption across elite networks, including Memorial Sloan Kettering (MSK), MD Anderson, Yale Cancer Center, Mount Sinai, and Texas Oncology.

Beyond the Registry Bottleneck: Why Triomics Raised $22M to Automate Oncology Record Curation

The clinical and operational lifecycles of modern oncology care are suffocating under an unprecedented data paradox. Cancer care is no longer constrained by a scarcity of clinical information; instead, it is profoundly bottlenecked by an inability to synthesize and act upon the massive datasets that already exist. A single oncology patient’s longitudinal record frequently expands into hundreds of narrative-heavy clinic notes, multi-page pathology and radiology profiles, genetic biomarker sequences, legacy external records, and historical treatment regimens.

Compounding this complexity is the rapid evolution of clinical trial eligibility protocols and National Comprehensive Cancer Network (NCCN) guidelines. Because legacy electronic health records (EHRs) function as passive digital filing cabinets rather than intelligent systems of action, oncology networks are forced to rely on manual chart scraping. Highly trained research coordinators, clinicians, and medical assistants spend hours manually auditing dense files to match patients to trials or compile mandatory state registries. This structural data fragmentation results in high operational friction, widespread clinical burnout, and missed enrollment windows for life-saving therapeutics.

To turn this multi-modal text overload into explainable, workflow-integrated intelligence, oncology infrastructure pioneer Triomics has finalized a $22 million Series B financing round. Led by Battery Ventures, with participation from existing backers Nexus Venture Partners, Lightspeed, and Y Combinator, alongside strategic healthcare networks like Oncology Ventures and Precision Health Informatics (Texas Oncology), the round brings Triomics’ total capitalization to more than $36 million. The funding will be deployed to expand its AI engineering teams, accelerate health system adoption, and scale its autonomous chart abstraction architecture across global provider and life sciences networks.

Source-Backed Reasoners vs. Lightweight Summarization

Founded in 2021 by Sarim Khan and Hrituraj Singh, Triomics completely bypasses the security risks of uncalibrated consumer LLMs by building a highly specialized oncology reasoning engine. While lightweight, general-purpose summarization software often drops vital clinical parameters or hallucinates critical diagnostic links, Triomics’ AI agents read the full longitudinal record to generate structured, explainable outputs. Crucially, every single algorithmic recommendation is source-backed, mathematically traceable, and entirely verifiable inside the clinician’s native workflow.

“Oncology is the hardest place to build AI, yet the most important,” stated Hrituraj Singh, co-founder and CTO of Triomics. “Getting a model to reason reliably across thousands of pages of notes, pathology, imaging, and evolving trial criteria, and show its work, is what separates a demo from software that clinicians actually use.”

This commitment to medical integrity has driven explosive adoption across elite academic cancer networks—including Memorial Sloan Kettering Cancer Center (MSK), MD Anderson, Yale Cancer Center, and Mount Sinai Tisch Cancer Center—as well as dominant community networks like Texas Oncology.

By deploying these autonomous agents, healthcare institutions are achieving dramatic operational efficiency. Peer-reviewed validation published in Nature Digital Medicine and presented before the American Society of Clinical Oncology (ASCO) demonstrates that Triomics users curb manual chart review times by 67%, while simultaneously expanding clinical trial matches by 40% and total enrollment numbers by over 30%.

Automating the Complex Cancer Registry Pipeline

Beyond immediate bedside triage and trial matching, Triomics is aggressively positioning its underlying AI infrastructure to handle the labor-intensive burden of cancer registry abstraction and mandatory reporting obligations. Lee Schwamm, MD, Chief Digital Health Officer at Yale New Haven Health System, emphasized that traditional chart abstraction is deeply subjective, slow, and challenging to complete within mandated federal timelines. Yale’s expanded integration with Triomics aims to deliver autonomous chart abstraction of true clinical registry quality, allowing human registrars to rapidly review and finalize data to comply with state, federal, and professional society reporting mandates without missing a beat.

Brandon Gleklen, Principal at Battery Ventures—who is joining the Triomics board of directors—noted that the company has built the precise infrastructure oncology has desperately required. Gleklen highlighted Triomics’ distinct platform leverage: the exact same underlying AI infrastructure seamlessly powers clinical trial matching, pre-visit chart preparation, and registry data abstraction without requiring redundant, costly EHR integrations. This architectural advantage delivers an undeniable operational moat within a highly coveted enterprise customer base.

What You Should Know

• AI-native pharmaceutical marketing platform Solstice has announced a $21M Series A funding round led by Transformation Capital, bringing its total funding footprint to approximately $25M.
• The financing, featuring participation from Twelve Below and Virtue Ventures, will be deployed to expand the company’s technical product architecture and accelerate customer-facing go-to-market functions.
• Solstice addresses a massive operational bottleneck where routine pharmaceutical marketing assets traditionally require three months to navigate rigid medical, legal, and regulatory (MLR) review pipelines.
• By pairing specialized generative algorithms with in-house medical experts, the platform compresses standard asset-delivery cycles from months down to just 10 days, moving concepts to formal MLR submission in under 48 hours.
• The platform automatically calculates compliance scores and has successfully reduced average enterprise MLR review cycles from 3.2 rounds down to 1.2 rounds per asset.

From 3 Months to 10 Days: Why Solstice Raised $21M to Automate Pharma MLR Workflows

The global biopharmaceutical sector is currently working through a high-stakes, time-sensitive commercialization crunch. While drug developers routinely invest billions of dollars to discover breakthrough molecular compounds, the legacy infrastructure responsible for translating clinical evidence into compliant marketing campaigns has remained entirely unchanged for decades. Today, biopharma brands spend upwards of $100 billion annually on commercialization efforts. Yet, even a routine marketing asset, such as a single healthcare provider (HCP) email, frequently takes up to three months to crawl through internal medical, legal, and regulatory (MLR) review boards.

In a market defined by steadily shrinking patent exclusivity windows, these administrative delays carry severe financial and human consequences. Every month an asset remains trapped in back-and-forth regulatory review directly compromises market share, delays necessary clinician outreach, and prevents life-altering therapeutics from reaching the patients who need them most. For modern brand managers, this operational friction makes delivering highly personalized, timely content across competitive therapeutic landscapes structurally impossible.

To eliminate this regulatory bottleneck and build a continuous system of action for life sciences commercialization, AI-native marketing agency Solstice has announced a $21M Series A funding round. Led by healthcare-focused investment giant Transformation Capital, with strategic participation from Twelve Below, Virtue Ventures, and other prominent backers, the $25M total funding moat will be deployed to fuel go-to-market expansion, scale internal product engineering, and expand customer-facing operations.

Grounding Claims in FDA Evidence via Proprietary Models

Solstice completely replaces traditional marketing agency workflows by pairing its proprietary pharmaceutical marketing models with in-house subject-matter specialists. Rather than forcing copywriters to manually parse dense clinical trials, the platform natively ingests a brand’s verified clinical data, official FDA filings, and approved scientific literature. This architecture constructs a highly grounded, compliant understanding of the asset, enabling the rapid generation of highly localized digital campaigns, programmatic advertisements, and coordinated patient-and-provider communications.

To guarantee absolute adherence to strict compliance guidelines without sacrificing creative quality, every generated asset undergoes an automated pre-screening review. Solstice’s models score each asset on its direct likelihood of capturing MLR approval before it ever routes to a human regulatory team.

“We built Solstice to help life sciences teams bring therapeutics to market faster by unifying content creation, medical review, and performance insights in a single AI-native system,” stated Aris Saxena, co-founder and CEO of Solstice. “Our customers used to run three review cycles per asset; now they run one or two at most, and content that used to take months goes out in 10 days. Most importantly, they create more personalized, higher-performing content that helps them compete in increasingly crowded biopharma markets.”

This automated predictability is delivering immediate, real-world returns for major enterprise brands. Kristine Saffrin, Marketing Director at Alexion Pharmaceuticals, noted that prior to deploying Solstice, securing a single marketing approval required weeks of operational friction that delayed product launches. By shifting to an integrated data-driven workflow, their teams now transition from initial draft to final approval in a matter of days, allowing them to confidently execute at the rapid pace modern digital brands demand.

Unlocking a 12x Acceleration in Campaign Launch Speeds

The performance metrics surrounding Solstice’s commercial footprint demonstrate a massive leap in operational output. By eliminating manual drafting bottlenecks, Solstice customers launch new campaigns 12 times faster than they would via legacy agencies. The timeline from an initial marketing concept to formal MLR submission is compressed to under 48 hours, making assets market-ready in roughly 10 days.

This extreme acceleration allows lean commercial teams to produce nearly three times more high-quality, targeted content per quarter. Crucially, it drives a major reduction in administrative friction—slashing the average number of required MLR review iterations from a punishing 3.2 rounds down to an agile 1.2 rounds per asset.

Vinay Shah, Partner and Founding Team Member at Transformation Capital, highlighted the intense macroeconomic necessity of this shift, stating that while drug commercialization is one of the most heavily regulated and valuable workflows in the entire healthcare ecosystem, it has been ignored by innovation for decades. By using domain-specific AI to optimize this layer, Solstice helps premium pharma brands capture major cost savings and speed-to-market advantages without ever compromising on safety or compliance standards. This immediate, auditable value has triggered rapid commercial growth for Solstice, which now serves over a dozen pharmaceutical organizations—including multiple top-20 global pharma brands across high-stakes therapeutic specialties such as oncology, immunology, and metabolic diseases.

What You Should Know

• Health technology leader Philips and The Walt Disney Company have launched an exclusive, global collaboration to integrate Disney characters and stories directly into Philips Ambient Experience for MRI suites across 87 countries.
• Pediatric MRI procedures are notoriously disruptive, with 66% of young patients reporting severe anxiety inside loud, unfamiliar machinery where they must lie completely still for up to 40 minutes.
• A clinical multi-center study conducted across six European hospitals revealed that Disney-themed audio-visual interventions slashed post-scan pediatric stress levels by 43% and dropped scan pauses by 63%.
• By mitigating anxiety-induced claustrophobia, the immersive platform reduces the clinical need for pediatric sedation, minimizes expensive re-scans, and creates a smoother, more predictable imaging workflow.
• As part of a massive charitable commitment to pediatric care, Disney has provided its artistic assets—including Mickey Mouse, Marvel superheroes, and Star Wars themes—to Philips at no cost.

Pediatric Imaging Redefined: Why Philips and Disney Are Turning Terrifying MRIs into Immersive Escapes

The diagnostic imaging pipeline for pediatric patients has long represented a highly volatile clinical and operational bottleneck for global health systems. Magnetic Resonance Imaging (MRI) machines are inherently intimidating environments for young children: they are massive, unfamiliar configurations that generate loud, rhythmic mechanical noises. Furthermore, the procedural mandate requires a child to remain perfectly motionless inside a claustrophobic bore for durations stretching up to 40 minutes.

The statistics highlighting this operational strain are stark: 66% of pediatric patients report acute anxiety and fear during standard MRI procedures. When a young patient panics, the clinical consequences cascade instantly. Movement during active sequences compromises image quality, triggering immediate scan pauses, elongated procedure times, or entirely aborted scans. To navigate this resistance, clinical teams are frequently forced to rely on pediatric sedation, which introduces clinical risks for the child and places heavy resource, staffing, and recovery demands on hospital staff. Ultimately, these routine disruptions choke daily patient throughput, lengthen regional wait times, and inflate the total cost of diagnostic care.

To dismantle this reactive paradigm and build an automated, anxiety-reducing system of action at the point of care, health technology giant Philips has finalized an exclusive global collaboration with The Walt Disney Company. By incorporating beloved Disney animation, Marvel superheroes, and Star Wars narratives directly into the Philips Ambient Experience for MRI platform, the partnership establishes a scalable, child-friendly environment across medical facilities in 87 countries worldwide.

The Clinical Blueprint: Converting Magic into Measurable Efficiency

The integration of consumer storytelling into an acute diagnostic workflow is backed by data from a rigorous, multi-center clinical study executed across six prominent European health systems, including Sant Joan de Déu Hospital in Barcelona and Herlev Hospital in Denmark. Investigators tracking the operational impact of Philips Ambient Experience paired with Disney-themed settings uncovered exceptional performance metrics:

• Stress Demolition: For pediatric patients between the ages of 6 and 10, post-scan stress levels were reduced by 43% compared to traditional, uncalibrated imaging baselines.
• Workflow Optimization: Crucially, the occurrence of unexpected pauses and motion-driven disruptions during active scans dropped by a staggering 63%.

Emilio J. Inarejos Clemente, representing the Department of Diagnostic Imaging at Sant Joan de Déu Hospital, emphasized that these audio-visual interventions do more than comfort a vulnerable child; they drive immediate workflow predictability. By significantly reducing scan disruptions, the system allows frontline technicians and radiologists to maintain maximum operational efficiency, protecting high-quality diagnostic output while allowing clinical networks to scan more pediatric patients each day.

Scale, Philanthropy, and the Digital Front Door

The Philips Ambient Experience utilizes dynamic, calming lighting architectures, synchronized acoustic soundscapes, and projection elements to alter a patient’s perception of the clinical space before and during an exam. Under this exclusive framework, children and families can independently select their preferred thematic guide—ranging from classic Mickey and Minnie Mouse environments to Star Wars worlds and Disney Princesses—to actively shift focus away from the medical machinery.

This integration builds on Disney’s extensive, $100 million corporate social responsibility commitment to pediatric care, which has modernized environments across more than 1,700 children’s hospitals in 45 nations. As part of this philanthropic initiative, Disney has delivered its high-value artistic assets to Philips at zero cost. To guarantee frictionless execution at the hospital level, thousands of global healthcare professionals have been trained via specialized Disney Institute programs to deliver a compassionate, reassuring patient experience. Early institutional adopters—including Rady Children’s Health in Orange County and Calderdale Royal Hospital—are already documenting immediate positive feedback from both staff and families.

The proposed Requiring Enhanced and Accurate Lists (REAL) Health Providers Act—also referred to as the RHP Act—recently signed and expected to take effect for plan year 2028, represents a significant shift in how healthcare providers are regulated, credentialed, and represented to Medicare Advantage members.

The proposed requirements aim to provide health plan members with greater transparency, accessibility, and accuracy within provider directories in their member portals. Payers will need to implement these new requirements while maintaining compliance and a high standard of consumer-centric service. As regulatory pressure intensifies, health plans must remain agile by modernizing processes and embracing technology so they can deliver value without disruptions as these new proposed regulations are enacted into law and subsequently enforced.

What the RHP Act regulations entail

The RHP Act will raise the bar for provider data accuracy, transparency, and timeliness. Under the RHP Act, payers will face financial sanctions for inaccurate or inconsistent directory data. New requirements include mandatory real-time updates to provider information within 48 hours of changes and the prompt removal of out-of-network providers. The RHP Act also includes standardized credentialing processes and more user-friendly directory formats for a more member-centric experience.

Increased directory analysis and verification will be needed to keep up with these requirements and avoid fines. This will be difficult for payers that have only had fragmented systems or faulty technology available to manage their data. It will require payers to rethink data management and accelerate efforts to modernize their infrastructure and maintain compliance. 

The RHP Act aims to eliminate ghost networks, where providers remain listed as in-network when they are no longer active or accepting new patients, or otherwise unavailable. The legislation seeks to ensure that consumers can find accurate information and connect with providers efficiently and reliably.

The impact on payers

Payers should be actively preparing for operational and compliance pressures resulting from the proposed legislation. Fragmented systems may lead to inaccurate data, which could then result in non-compliance and sanctions. Organizations need to implement structured, efficient workflows that track provider status and ensure data accuracy. Consolidating systems can help ensure that data is accurate and constantly up to date. 

Further, manual processes can be difficult to manage and maintain. Managing provider networks requires a strong data infrastructure and systems in place to meet the new time requirements. Human error, as well as time management, may act as barriers to implementing these changes. The requirement to update directory information within 48 hours and maintain ongoing verification could strain manual or fragmented workflows. 

Payers face expanded compliance risk, both due to the financial penalties associated with the proposed legislation, as well as the potential for reputational harm and a decrease in member trust. For many payers, compliance under the RHP Act will require a system-wide shift in how they manage, verify and publish provider network data.

Strategic navigation of the RHP Acts’s new guidance

Given the potential impact, payers should consider a proactive and strategic approach to preparing for the regulatory changes and navigating the transformation smoothly.

The ability to adapt quickly will help organizations in the long run, not just in maintaining compliance but also in maintaining a strong reputation rooted in member trust and transparency.

Organizations should be evaluating current systems and identifying areas for improvement. A critical first step is assessing current workflows to understand how provider information is being collected and processed and where inconsistencies arise. Going forward, organizations should regularly evaluate their processes and technology to ensure smooth operations, moving away from periodic verification cycles to a continuous, rapid review structure.

Establishing clear governance is also important to define which teams are responsible for tracking, validating and updating changes in provider data, so directories stay up to date. Directories must contain complete, member-relevant information, including information on specialties, practice locations, and availability, to avoid ghost network designations.

Finally, payers should maintain detailed audit trails and documentation of directory updates. This helps to reduce compliance risk and create a more reliable, member-centered provider data model.

Where technology can support teams and standardize efficiency

As the RHP Act sets tighter standards, technology will be a necessary tool to help payers maintain compliance. Provider data management tools are widely used across the payer community to address challenges in maintaining provider directories, and the proper infrastructure can consolidate data into a single source of truth.

Adding automation to these necessary workflows can streamline capabilities and ensure real-time updates to provider status, practice details and credentials, pushing updates to directories swiftly, addressing a key provision of the RHP Act. This eliminates the need for manual entry, which comes with the potential for human error and is extremely time-consuming for staff and would be difficult to maintain with new timeline requirements. 

Technology also offers the opportunity for increased analytics and AI implementation to make recommendations to streamline and build checks directly into workflows that ensure compliance and identify data discrepancies early on to maintain documentation ahead of audits. Automated platforms also offer more user-friendly processes to keep up with the RHP Act standards for members. These functions improve information accessibility and empower members to navigate platforms with ease. With the proper foundation in place, payers can confidently present directories that are accurate and updated, ultimately improving member trust, reducing friction, and maintaining the RHP Act standards.

With the help of automation and data tools, organizations can transform provider data management from a reactive, time-consuming operation into a proactive, reliable asset.

Operational readiness that backs compliance and builds trust

The REAL Health Providers Act is shifting how provider directories are regulated, making increased accuracy, transparency, and timeliness a necessity. While the operational and compliance burdens may be significant, maintaining an always-on response to regulatory changes comes with benefits to reputation and member trust.

With an effective strategy and an investment in technology-backed data practices, teams can strengthen relationships with providers, members and staff members, through increased efficiency, user satisfaction and reduction of the administrative burden on staff members. Embracing accurate provider data management will help keep payers in compliance while building trust, showing the opportunity for alignment when operations and regulations are prioritized. 

About Lynne Rinehimer, Esq.

Lynne Rinehimer has worked in the healthcare compliance field for over 25 years. Starting her career in consulting, Lynne drafted compliance programs, served as part of the Independent Review Organization for entities under corporate integrity agreements, and led education sessions for compliance and clinical teams. Lynne manages the content in the symplr Compliance (ComplyTrack) Risk Assessment Management Solution, conducts product demonstrations, and serves as a subject matter expert and thought leader, conducting webinars throughout the year on a variety of compliance-related topics. Lynne is an attorney and a member of the Pennsylvania Bar Association.

What You Should Know

• GoodRx has officially launched GoodRx Companion, a new $14.99-per-month membership program designed to lower out-of-pocket consumer expenditures across everyday clinical touchpoints.
• Moving beyond transaction-focused pharmacy coupons, the subscription unifies free access to more than 200 common generic medications with hundreds more priced under $10 at nearly every domestic retail pharmacy.
• The platform integrates direct-to-consumer clinical workflows, featuring $19 virtual urgent care telehealth visits via GoodRx Care for routine conditions like UTIs, flu, and dermatology needs.
• Expanding into ancillary healthcare layers, the program offers pre-negotiated consumer savings on dental procedures, vision care, and major diagnostic testing including MRIs, CT scans, and comprehensive hormone panels.
• The launch drives GoodRx’s overarching subscription strategy, shifting the business model from episodic prescription discount cards toward diversified, recurring monthly revenue streams.

Beyond the Single Prescription: GoodRx Companion Launches $14.99 Monthly Membership for Continuum Care

The commercial landscape of American healthcare is currently defined by a punitive structural paradox. Over the past decade, enterprise employers and insurance plans have aggressively shifted financial liability directly onto the end consumer, leading to a steady increase in high-deductible health plans, narrower network restrictions, and soaring out-of-pocket medical costs. Today, holding health insurance no longer guarantees affordable care. Patients are increasingly forced to manage complex coverage limitations, paying full cash rates at the point of service for routine doctor visits, diagnostic work, and vital pharmaceutical therapies.

For individuals managing chronic, multi-medication conditions, this friction creates immediate care barriers. When everyday medical needs become financially unpredictable, compliance drops—patients skip critical follow-up appointments, delay preventative screenings, or leave necessary prescriptions un-filled at the pharmacy counter.

To address this financial friction and move past isolated transaction-based coupons, prescription savings giant GoodRx has announced the launch of GoodRx Companion. Positioned as a comprehensive $14.99-per-month subscription, the program unifies retail pharmacy relationships, affordable virtual medicine, and diagnostic savings into a singular, predictable monthly membership designed to help consumers reclaim control over their healthcare expenditures.

From Episodic Transactions to an Integrated Care Loop

The introduction of GoodRx Companion marks a critical evolution in how the company interacts with its base of nearly 25 million annual consumers. Wendy Barnes, President and CEO of GoodRx, emphasized that as insurance coverage grows increasingly complex, individuals require trusted, structural solutions that deliver clearer baseline value. Companion addresses this demand by wrapping an array of routine healthcare needs into a single digital ecosystem:

• Direct Pharmaceutical Infrastructure: Members gain completely free access to more than 200 common generic medications, alongside hundreds of additional generic therapies priced under $10, redeemable at nearly every retail pharmacy nationwide.
• Integrated Virtual Triage: The platform embeds $19 telehealth consultations through GoodRx Care, allowing users to instantly navigate routine conditions such as UTIs, skin care concerns, and the flu without enduring long urgent care wait times or expensive facility fees.
• Ancillary Network Savings: Moving outside the traditional pharmacy footprint, the membership offers significant discounted cash pricing on dental procedures (including cleanings, exams, and crowns), vision care (covering eye exams, corrective lenses, and laser surgery), and critical diagnostic testing. This includes significant savings on high-cost imaging services like MRIs, CT scans, ultrasounds, and comprehensive wellness or hormone lab panels.

By linking clinical validation, diagnostic access, and medication fulfillment into a unified monthly subscription, GoodRx systematically eliminates the data fragmentation and price obscurity that historically drive consumers away from necessary medical upkeep.

Stabilizing Favorable Pharmacy Economics

For GoodRx, the launch of Companion represents a deliberate strategic pivot toward an enterprise-grade subscription framework. While the company has previously deployed highly successful, condition-focused vertical tracks for weight loss, erectile dysfunction, and hair loss management, Companion functions as a broad-spectrum membership built for the entire household.

This evolution alters the company’s underlying revenue architecture. By transitioning episodic, one-off coupon users into highly continuous, recurring monthly membership relationships, GoodRx creates a highly predictable, recurring revenue stream. This structural shift drastically enhances long-term consumer lifetime value while simultaneously strengthening the platform’s alignment with retail pharmacies through highly favorable, standardized cash-pay economics.

What You Should Know

• The University of Pennsylvania Health System (UPHS) has announced a multi-year collaboration with primary care AI leader K Health to deploy a suite of integrated clinical agents across its network EHR platforms.
• The rollout kicks off within the Penn Medicine On-Demand virtual urgent care program before expanding into in-person primary care, cardiology, and dermatology clinics.
• The AI engine features a clinically validated, peer-reviewed intake interface that dynamically interviews patients to generate a pre-populated draft chart inside the provider’s EHR before the encounter begins.
• Built to eliminate point-of-care bottlenecks, the platform understands complex medical language, symptom profiles, medication tracking, and the clinical ambiguity native to everyday conditions.
• Backed by $384M in total venture financing, K Health and Penn Medicine will also co-develop peer-reviewed research to expand the global evidence base for routine clinical AI automation.

Beyond the Point Solution: Why Penn Medicine Is Integrating K Health AI Agents Across Its Core EHR

The front doors of America’s premier academic health systems are facing an unprecedented capacity crunch. Patient volumes are rising across both virtual and brick-and-mortar care channels, leaving clinical teams to combat severe administrative overhead and charting bottlenecks. Historically, provider organizations have attempted to manage this stress by layering disconnected digital health point solutions onto their existing infrastructure—deploying standalone chatbots, separate intake forms, and isolated text-based tools.

In practice, these fragmented applications often exacerbate data silos, forcing clinicians to manually transfer patient details and toggle between multiple screens. The resulting friction increases wait times, heightens the risk of information gaps, and pulls doctors away from the high-acuity decisions that demand their advanced medical training.

To dismantle these administrative silos and hardwire an automated, system-wide intake layer directly into its core infrastructure, the University of Pennsylvania Health System (UPHS) has finalized a multi-year partnership with K Health. Moving past superficial point solutions, Penn Medicine is integrating K Health’s clinical AI agents directly into its existing electronic health record (EHR) systems and public-facing portal interfaces. This deployment aims to streamline the pre-visit data loop, insulate physicians from charting fatigue, and establish a safe, navigable digital environment for patients throughout their care journey.

Pre-Populating the Chart: Automated Intake with Medical Context

The collaboration will initially launch within Penn Medicine On-Demand—the health system’s virtual urgent care framework—before expanding into the network’s in-person primary care clinics and high-volume specialty divisions, including cardiology and dermatology.

The engine driving this clinical automation is K Health’s peer-reviewed, clinically validated patient intake interface. When a patient initiates a request for care, the platform opens an active, conversational dialogue. Rather than prompting the user with a static, rigid questionnaire, the agent guides the patient through a dynamically personalized encounter tailored to their described reason for the visit.

As the patient interacts with the interface, the underlying algorithms translate natural symptoms, active medications, and historical care timelines into structured medical data. This automated synthesis generates a pre-populated draft clinical chart that flows directly into the physician’s EHR, remaining fully visible and ready for review before the consultation ever begins.

Mitchell Schnall, MD, PhD, Senior Vice President for Data and Technology Solutions at Penn Medicine, noted that the health system views AI as a significant clinical opportunity to optimize direct patient care. By deploying this native system-level integration, Penn Medicine can thoroughly evaluate how advanced AI models scale across the entire spectrum of routine institutional care.

Training AI on Real-World Medical Interactions

A primary reason general-purpose artificial intelligence models routinely fail when deployed in an acute healthcare setting is their fundamental lack of domain-specific clinical nuance. Medical communication is rarely binary; it is filled with shorthand terminology, nuanced diagnostic codes, and intense situational ambiguity.

K Health addresses this safety hurdle by training its enterprise clinical agents exclusively on large lakes of real-world medical interactions and verified clinical datasets. This specific grounding ensures the platform natively understands the language of medicine, allowing it to safely interpret complex patient inputs and match them to standardized clinical pathways.

Ran Shaul, Co-founder and Chief Product Officer of K Health, emphasized that as health systems globally race to construct their consumer-facing digital strategies, Penn Medicine is treating clinical AI as foundational infrastructure. The software functions as a continuous layer that prepares the provider visit, optimizes workflow coordination, and seamlessly routes patient inquiries into an auditable pathway.

To further cement this framework, Penn Medicine and K Health are aligning to launch collaborative, peer-reviewed clinical research initiatives. Building on K Health’s prior academic publications tracking chronic disease management and primary care automation, the joint research projects will focus on developing a rigorous, evidence-based benchmark for how autonomous agents impact workflow efficiency and patient compliance over time.

What You Should Know

• The Coalition for Health AI (CHAI) has officially released a series of in-depth healthcare AI governance playbooks to establish essential baseline controls for safe, transparent technology deployment.
• Developed by more than 150 industry leaders spanning 100+ diverse healthcare organizations, the guidelines are engineered to scale across all care environments, from major academic medical centers to resource-constrained community health clinics.
• The playbooks provide the foundational framework that maps directly to the upcoming voluntary AI certification being developed by the Joint Commission.
• The open-source documentation structures responsible clinical AI implementation across eight critical elements, including lifecycle management, risk and impact assessments, and responsible data usage.
• The playbooks will act as a baseline guide for CHAI’s Governance Platform Partners, offering health systems a standardized, auditable framework to evaluate vendor software compliance.

Turning Intent into Evidence: Why CHAI’s New Playbooks Are the Core of Hospital AI Governance

The integration of artificial intelligence into clinical and operational healthcare workflows has advanced at a velocity completely unprecedented in digital health history. However, as hospitals and health systems race to adopt automated administrative solutions, diagnostic tools, and predictive models, they have collided with a major operational bottleneck. The industry has historically lacked a practical, consistent, and standardized framework to audit these technologies.

Without repeatable baseline controls, hospital IT committees and clinical leaders have been forced to design independent, uncalibrated review processes. This fragmented approach increases risk, fuels clinician skepticism, and leaves organizations highly exposed to software errors, data liabilities, and algorithmic bias.

To bridge this validation gap and convert responsible AI concepts into a practical, repeatable system of action, the Coalition for Health AI (CHAI) has released its highly anticipated series of comprehensive governance playbooks. Developed through extensive industry collaboration and community workshops, these playbooks arm healthcare delivery organizations with a standardized, auditable framework to integrate baseline safety controls directly into their existing infrastructure.

Democratizing Guardrails Across Academic and Safety-Net Clinics

A primary limitation of early digital health standards was their tendency to over-index on the massive financial and technical resources of top-tier academic medical centers. These complex frameworks frequently left regional care facilities, safety-net systems, and community health centers without an actionable path forward.

To ensure the new guidelines reflect true clinical realities, CHAI convened a working group of more than 150 health AI leaders representing over 100 diverse healthcare delivery organizations. Merage Ghane, PhD, Director of Responsible AI at CHAI, emphasized that the project was strictly guided by real-world operational challenges, lessons learned, and the specific resource constraints facing frontline providers.

Dr. Brian Anderson, CEO of CHAI, noted that the resulting playbooks are intentionally designed to democratize AI innovation. By making responsible AI usable for health systems regardless of their individual size or budget, the coalition ensures that any provider can safely translate advanced automation into highly secure, equitable, and transparent patient care.

Importantly, the risk-based, scalable architecture has won praise from community health leaders. Chandra Beasley, Director of IT at the South Carolina Primary Health Care Association, noted that the guidance directly accounts for the shared-services models and capacity boundaries that define community health centers, allowing localized clinics to advance health equity and maintain patient safety without choking under administrative strain.

The Eight Pillars of Auditable AI Architecture

Rather than offering generic or purely theoretical advice, the CHAI playbooks provide definitive implementation guidance, evaluation tools, and reusable resources to map software against eight critical dimensions of organizational risk:

1. Organizational AI Policy: Establishing the core philosophical and ethical guidelines for technology deployment.
2. Organizational Structure: Defining corporate lines of accountability and institutional ownership.
3. Organizational Resources: Budgeting and allocating the human and technical capital needed to monitor models.
4. Responsible AI Lifecycle Management: Tracking an application from initial vetting through active deployment and eventual decommissioning.
5. Risk and Impact Assessments: Executing strict pre- and post-implementation reviews to identify clinical drift or unintended consequences.
6. Responsible Data Management and Use: Securing patient data integrity and ensuring strict, compliant information use.
7. Third-Party Management: Auditing vendor compliance and establishing clear liability boundaries for commercial software.
8. Education, Training, and Feedback: Hardwiring continuous learning models to ensure frontline staff are fully equipped to use these tools without risking professional de-skilling.

Crucially, this structured framework does not merely serve as an internal reference sheet. The playbooks are engineered to provide the exact foundational framework necessary to achieve the upcoming, voluntary AI certification currently being developed by the Joint Commission. Dr. Jonathan Perlin, President and CEO of the Joint Commission, stated that these playbooks represent a massive milestone in fulfilling the cross-industry promise to ensure American healthcare organizations are fully prepared to implement AI safely and responsibly.